Press Releases

Date Title
January 25, 2022 Progenity Strengthens Intellectual Property for Single-Molecule Detection Technology with Additional Patent
SAN DIEGO, Jan. 25, 2022 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), an innovative biotechnology company, today announced the award of another new patent related to its single-molecule detection assay platform under development. The USPTO has issued U.S. Patent No.
January 11, 2022 Progenity Announces Oral Presentation on Treatment of Gastrointestinal Disorders at 34th Belgian Week of Gastroenterology
Dr. Bram Verstockt to present patient data establishing correlation between drug levels in colon and clinical outcomes SAN DIEGO, Jan. 11, 2022 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a biotechnology company innovating in the field of oral biotherapeutics for gastrointestinal health and
January 5, 2022 Progenity Announces Acceptance of Two Abstracts on Treatment of Gastrointestinal Disorders at ECCO’22
SAN DIEGO, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a biotechnology company innovating in the field of oral biotherapeutics for gastrointestinal health and beyond, today announced that two presentations with patient data on indicators of efficacy in the treatment of
January 3, 2022 Progenity to Participate in the H.C. Wainwright BIOCONNECT Virtual Conference
SAN DIEGO, Jan. 03, 2022 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a biotechnology company innovating in the field of oral biotherapeutics for gastrointestinal health and beyond, today announced that the company will participate in a pre-recorded presentation at the H.C.
December 20, 2021 Progenity Completes Exit from Laboratory Business with Sale of Affiliate Lab
Transaction Adds Cash to Balance Sheet and Further Reduces Operating Expenses SAN DIEGO, Dec. 20, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a biotechnology company innovating in the field of oral biotherapeutics for gastrointestinal health and beyond, today announced it has
December 2, 2021 Progenity Announces New Patent for Single-Molecule Detection Technology
SAN DIEGO, Dec. 02, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a biotechnology company innovating in the fields of gastrointestinal health and oral biotherapeutics, today announced a new patent related to its single-molecule detection platform under development.
November 23, 2021 Progenity Strengthens its Liquidity Position
Company received more than $44 million in warrant exercises since August 2021. Current liquidity position provides runway to achieve critical research and development milestones through 2022. SAN DIEGO, Nov. 23, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc.
November 15, 2021 Progenity to Participate in the Piper Sandler 33rd Annual Virtual Healthcare Conference
SAN DIEGO, Nov. 15, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), an innovative biotechnology company, today announced that the company will participate in a pre-recorded fireside chat at the Piper Sandler 33rd Annual Virtual Healthcare Conference, which will be available on the
November 10, 2021 Progenity Provides Corporate Update and Reports Third Quarter 2021 Financial Results
Added important patents further protecting the company’s therapeutic delivery technologies Added strong biotherapeutics capabilities to management team and board of directors Implemented cost-cutting measures expected to result in approximately $145 million in cost savings on an annual basis 1
November 9, 2021 Progenity Appoints Adi Mohanty as Chief Executive Officer
SAN DIEGO, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), an innovative biotechnology company, today announced the appointment of Adi Mohanty as Chief Executive Officer of the company, effective November 8, 2021. Mr. Mohanty also joins the Progenity Board of Directors.
Displaying 1 - 10 of 103